A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference30 articles.
1. Non-small cell lung cancer: current treatment and future advances;Zappa;Transl Lung Cancer Res,2016
2. NCCN Guidelines® insights: non-small cell lung cancer, Version 4.2016;Ettinger;J Natl Compr Cancer Netw,2016
3. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy;Kazandjian;Oncologist,2016
4. Patients treated with platinum-doublet chemotherapy for advanced non-small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation;Paramanathan;Clin Lung Cancer,2013
5. Meta-analysis of first-line pemetrexed plus platinum treatment in compared to other platinum-based doublet regimens in elderly East Asian patients with advanced nonsquamous non-small-cell lung cancer;Lu;Clin Lung Cancer,2016
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Elevated levels of neutrophil related chemokine citrullinated histone H3, interleukin-8 and C-reaction protein in patients with immune checkpoint inhibitor therapy: predictive biomarkers for response to treatment;Cancer Cell International;2023-08-14
2. Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer Immunity;Advanced Science;2022-12-25
3. Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors;Cancers;2022-07-15
4. Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy;Genes & Diseases;2022-02
5. Elevated Expression Levels of Neutrophil Related Chemokine Citrullinated Histone H3, Interleukin-8 and C- Reactive Protein in Patients with Immune Checkpoint Inhibitor Therapy: Predictive Biomarkers for Response to Treatment;SSRN Electronic Journal;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3